Clinical Trials Browser

Completed × OTHER_GOV × anlotinib × Clear all

NCT04660097 2026-04-08

Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

Phase 2 Completed

Small Cell Lung Carcinoma

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Phase 2 Completed

Neoplasm Metastasis